Fibrolamellar Carcinoma Differential Diagnoses

  • Author: Michael A Choti, MD, MBA, FACS; Chief Editor: Jules E Harris, MD   more...
 
Updated: Jan 13, 2012
 
 

Differential Diagnoses

Proceed to Workup
 
 
Contributor Information and Disclosures
Author

Michael A Choti, MD, MBA, FACS  Jacob C Handelsman Professor of Surgery, Professor of Oncology, Radiology, Engineering, Johns Hopkins University School of Medicine

Michael A Choti, MD, MBA, FACS is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Surgeons, American Hepato-Pancreato-Biliary Association, American Society of Clinical Oncology, American Surgical Association, Association for Academic Surgery, International Hepato-Pancreato-Biliary Association, Society for Surgery of the Alimentary Tract, Society of Surgical Oncology, and Society of University Surgeons

Disclosure: Nothing to disclose.

Coauthor(s)

Hari Nathan, MD  House Staff, Department of Surgery, The Johns Hopkins Hospital; Postdoctoral Fellow, Department of Surgery, The Johns Hopkins University School of Medicine

Hari Nathan, MD is a member of the following medical societies: American College of Surgeons, American Hepato-Pancreato-Biliary Association, Association for Academic Surgery, and Society for Surgery of the Alimentary Tract

Disclosure: Nothing to disclose.

Specialty Editor Board

Lodovico Balducci, MD  Professor of Oncology and Medicine, University of South Florida College of Medicine; Division Chief, Senior Adult Oncology Program, H Lee Moffitt Cancer Center and Research Institute

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Troy H Guthrie, Jr, MD  Director of Cancer Institute, Baptist Medical Center

Troy H Guthrie, Jr, MD is a member of the following medical societies: American Federation for Medical Research, American Medical Association, American Society of Hematology, Florida Medical Association, Medical Association of Georgia, and Southern Medical Association

Disclosure: Nothing to disclose.

Rajalaxmi McKenna, MD, FACP  Southwest Medical Consultants, SC, Department of Medicine, Good Samaritan Hospital, Advocate Health Systems

Rajalaxmi McKenna, MD, FACP is a member of the following medical societies: American Society of Clinical Oncology, American Society of Hematology, and International Society on Thrombosis and Haemostasis

Disclosure: Nothing to disclose.

Chief Editor

Jules E Harris, MD  Clinical Professor of Medicine, Section of Hematology/Oncology, University of Arizona College of Medicine, Arizona Cancer Center

Jules E Harris, MD is a member of the following medical societies: American Association for Cancer Research, American Association for the Advancement of Science, American Association of Immunologists, American Society of Hematology, and Central Society for Clinical Research

Disclosure: GlobeImmune Salary Consulting

References

  1. Edmondson HA. Differential diagnosis of tumors and tumor-like lesions of liver in infancy and childhood. AMA J Dis Child. Feb 1956;91(2):168-86. [Medline].

  2. Craig JR, Peters RL, Edmondson HA, et al. Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinico-pathologic features. Cancer. Jul 15 1980;46(2):372-9. [Medline].

  3. Berman MM, Libbey NP, Foster JH. Hepatocellular carcinoma. Polygonal cell type with fibrous stroma--an atypical variant with a favorable prognosis. Cancer. Sep 15 1980;46(6):1448-55. [Medline].

  4. Farhi DC, Shikes RH, Murari PJ, et al. Hepatocellular carcinoma in young people. Cancer. Oct 15 1983;52(8):1516-25. [Medline].

  5. Stromeyer FW, Ishak KG, Gerber MA, et al. Ground-glass cells in hepatocellular carcinoma. Am J Clin Pathol. Sep 1980;74(3):254-8. [Medline].

  6. Klein WM, Molmenti EP, Colombani PM, et al. Primary liver carcinoma arising in people younger than 30 years. Am J Clin Pathol. Oct 2005;124(4):512-8. [Medline].

  7. Torbenson M. Review of the clinicopathologic features of fibrolamellar carcinoma. Adv Anat Pathol. May 2007;14(3):217-23. [Medline].

  8. Kannangai R, Vivekanandan P, Martinez-Murillo F, et al. Fibrolamellar carcinomas show overexpression of genes in the RAS, MAPK, PIK3, and xenobiotic degradation pathways. Hum Pathol. Apr 2007;38(4):639-44. [Medline].

  9. Vivekanandan P, Torbenson M. Epigenetic instability is rare in fibrolamellar carcinomas but common in viral-associated hepatocellular carcinomas. Mod Pathol. Jun 2008;21(6):670-5. [Medline].

  10. Ward SC, Waxman S. Fibrolamellar carcinoma: a review with focus on genetics and comparison to other malignant primary liver tumors. Semin Liver Dis. Feb 2011;31(1):61-70. [Medline].

  11. Farhi DC, Shikes RH, Silverberg SG. Ultrastructure of fibrolamellar oncocytic hepatoma. Cancer. Aug 15 1982;50(4):702-9. [Medline].

  12. Saul SH, Titelbaum DS, Gansler TS, et al. The fibrolamellar variant of hepatocellular carcinoma. Its association with focal nodular hyperplasia. Cancer. Dec 15 1987;60(12):3049-55. [Medline].

  13. Imkie M, Myers SA, Li Y, et al. Fibrolamellar hepatocellular carcinoma arising in a background of focal nodular hyperplasia: a report of 2 cases. J Reprod Med. Aug 2005;50(8):633-7. [Medline].

  14. Vecchio FM, Fabiano A, Ghirlanda G, et al. Fibrolamellar carcinoma of the liver: the malignant counterpart of focal nodular hyperplasia with oncocytic change. Am J Clin Pathol. Apr 1984;81(4):521-6. [Medline].

  15. Vecchio FM. Fibrolamellar carcinoma of the liver: a distinct entity within the hepatocellular tumors. A review. Appl Pathol. 1988;6(2):139-48. [Medline].

  16. El-Serag HB, Davila JA. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. Hepatology. Mar 2004;39(3):798-803. [Medline].

  17. Arista-Nasr J, Gutierrez-Villalobos L, Nuncio J, et al. Fibrolamellar hepatocellular carcinoma in mexican patients. Pathol Oncol Res. 2002;8(2):133-7. [Medline].

  18. Haas JE, Muczynski KA, Krailo M, et al. Histopathology and prognosis in childhood hepatoblastoma and hepatocarcinoma. Cancer. Sep 1 1989;64(5):1082-95. [Medline].

  19. Katzenstein HM, Krailo MD, Malogolowkin MH, et al. Fibrolamellar hepatocellular carcinoma in children and adolescents. Cancer. Apr 15 2003;97(8):2006-12. [Medline].

  20. Nagorney DM, Adson MA, Weiland LH, et al. Fibrolamellar hepatoma. Am J Surg. Jan 1985;149(1):113-9. [Medline].

  21. Kakar S, Burgart LJ, Batts KP, et al. Clinicopathologic features and survival in fibrolamellar carcinoma: comparison with conventional hepatocellular carcinoma with and without cirrhosis. Mod Pathol. Nov 2005;18(11):1417-23. [Medline].

  22. Saab S, Yao F. Fibrolamellar hepatocellular carcinoma. Case reports and a review of the literature. Dig Dis Sci. Oct 1996;41(10):1981-5. [Medline].

  23. Hemming AW, Langer B, Sheiner P, et al. Aggressive surgical management of fibrolamellar hepatocellular carcinoma. J Gastrointest Surg. Jul-Aug 1997;1(4):342-6. [Medline].

  24. El-Gazzaz G, Wong W, El-Hadary MK, et al. Outcome of liver resection and transplantation for fibrolamellar hepatocellular carcinoma. Transpl Int. 2000;13 Suppl 1:S406-9. [Medline].

  25. Kanai T, Takabayashi T, Kawano Y, et al. A case of postoperative recurrence of fibrolamellar hepatocellular carcinoma with increased vitamin B12 binding capacity in a young Japanese female. Jpn J Clin Oncol. Jun 2004;34(6):346-51. [Medline].

  26. Debray D, Pariente D, Fabre M, et al. Fibrolamellar hepatocellular carcinoma: report of a case mimicking a liver abscess. J Pediatr Gastroenterol Nutr. Nov 1994;19(4):468-72. [Medline].

  27. Soyer P, Roche A, Levesque M. Fibrolamellar hepatocellular carcinoma presenting with obstructive jaundice. A report of two cases. Eur J Radiol. Nov-Dec 1991;13(3):196-8. [Medline].

  28. Eckstein RP, Bambach CP, Stiel D, et al. Fibrolamellar carcinoma as a cause of bile duct obstruction. Pathology. Oct 1988;20(4):326-31. [Medline].

  29. Agarwal VR, Takayama K, Van Wyk JJ, et al. Molecular basis of severe gynecomastia associated with aromatase expression in a fibrolamellar hepatocellular carcinoma. J Clin Endocrinol Metab. May 1998;83(5):1797-800. [Medline].

  30. McCloskey JJ, Germain-Lee EL, Perman JA, et al. Gynecomastia as a presenting sign of fibrolamellar carcinoma of the liver. Pediatrics. Sep 1988;82(3):379-82. [Medline].

  31. Buetow PC, Pantongrag-Brown L, Buck JL, et al. Focal nodular hyperplasia of the liver: radiologic-pathologic correlation. Radiographics. Mar 1996;16(2):369-88. [Medline].

  32. Okada K, Kim YI, Nakashima K, et al. Fibrolamellar hepatocellular carcinoma coexistent with a hepatocellular carcinoma of common type: report of a case. Surg Today. 1993;23(7):626-31. [Medline].

  33. Okano A, Hajiro K, Takakuwa H, et al. Fibrolamellar carcinoma of the liver with a mixture of ordinary hepatocellular carcinoma: a case report. Am J Gastroenterol. Jul 1998;93(7):1144-5. [Medline].

  34. Seitz G, Zimmermann A, Friess H, Büchler MW. Adult-type hepatocellular carcinoma in the center of a fibrolamellar hepatocellular carcinoma. Hum Pathol. Jul 2002;33(7):765-9. [Medline].

  35. Morise Z, Sugioka A, Mizoguchi Y, et al. Fibrolamellar carcinoma of the liver in a Japanese hepatitis B virus carrier. J Gastroenterol Hepatol. Jul 2005;20(7):1136-8. [Medline].

  36. Stipa F, Yoon SS, Liau KH, et al. Outcome of patients with fibrolamellar hepatocellular carcinoma. Cancer. Mar 15 2006;106(6):1331-8. [Medline].

  37. Yamamoto H, Watanabe K, Nagata M, et al. Transformation of fibrolamellar carcinoma to common hepatocellular carcinoma in the recurrent lesions of the rectum and the residual liver: a case report. Jpn J Clin Oncol. Sep 1999;29(9):445-7. [Medline].

  38. Chang YC, Dai YC, Chow NH. Fibrolamellar hepatocellular carcinoma with a recurrence of classic hepatocellular carcinoma: a case report and review of Oriental cases. Hepatogastroenterology. Sep-Oct 2003;50(53):1637-40. [Medline].

  39. Tanaka K, Honna T, Kitano Y, et al. Combined fibrolamellar carcinoma and cholangiocarcinoma exhibiting biphenotypic antigen expression: a case report. J Clin Pathol. Aug 2005;58(8):884-7. [Medline].

  40. Ichikawa T, Federle MP, Grazioli L, et al. Fibrolamellar hepatocellular carcinoma: pre- and posttherapy evaluation with CT and MR imaging. Radiology. Oct 2000;217(1):145-51. [Medline].

  41. Paradinas FJ, Melia WM, Wilkinson ML, et al. High serum vitamin B12 binding capacity as a marker of the fibrolamellar variant of hepatocellular carcinoma. Br Med J (Clin Res Ed). Sep 25 1982;285(6345):840-2. [Medline].

  42. Sheppard KJ, Bradbury DA, Davies JM, et al. High serum vitamin B12 binding capacity as a marker of the fibrolamellar variant of hepatocellular carcinoma. Br Med J (Clin Res Ed). Jan 1 1983;286(6358):57. [Medline].

  43. Collier NA, Weinbren K, Bloom SR, et al. Neurotensin secretion by fibrolamellar carcinoma of the liver. Lancet. Mar 10 1984;1(8376):538-40. [Medline].

  44. Brandt DJ, Johnson CD, Stephens DH, et al. Imaging of fibrolamellar hepatocellular carcinoma. AJR Am J Roentgenol. Aug 1988;151(2):295-9. [Medline].

  45. Corrigan K, Semelka RC. Dynamic contrast-enhanced MR imaging of fibrolamellar hepatocellular carcinoma. Abdom Imaging. Mar-Apr 1995;20(2):122-5. [Medline].

  46. Gabata T, Matsui O, Kadoya M, et al. Delayed MR imaging of the liver: correlation of delayed enhancement of hepatic tumors and pathologic appearance. Abdom Imaging. May-Jun 1998;23(3):309-13. [Medline].

  47. Soyer P, Roche A, Levesque M, et al. CT of fibrolamellar hepatocellular carcinoma. J Comput Assist Tomogr. Jul-Aug 1991;15(4):533-8. [Medline].

  48. Soyer P, Bluemke DA, Vissuzaine C, et al. CT of hepatic tumors: prevalence and specificity of retraction of the adjacent liver capsule. AJR Am J Roentgenol. May 1994;162(5):1119-22. [Medline].

  49. Blachar A, Federle MP, Ferris JV, et al. Radiologists' performance in the diagnosis of liver tumors with central scars by using specific CT criteria. Radiology. May 2002;223(2):532-9. [Medline].

  50. Titelbaum DS, Hatabu H, Schiebler ML, et al. Fibrolamellar hepatocellular carcinoma: MR appearance. J Comput Assist Tomogr. Jul-Aug 1988;12(4):588-91. [Medline].

  51. Hamrick-Turner JE, Shipkey FH, Cranston PE. Fibrolamellar hepatocellular carcinoma: MR appearance mimicking focal nodular hyperplasia. J Comput Assist Tomogr. Mar-Apr 1994;18(2):301-4. [Medline].

  52. Hui MS, Choi WM, Perng HL, et al. Fibrolamellar hepatocellular carcinoma--an atypical MR manifestation. Hepatogastroenterology. Mar-Apr 1998;45(20):514-7. [Medline].

  53. Adam A, Gibson RN, Soreide O, et al. The radiology of fibrolamellar hepatoma. Clin Radiol. Jul 1986;37(4):355-8. [Medline].

  54. Miller WJ, Federle MP, Campbell WL. Diagnosis and staging of hepatocellular carcinoma: comparison of CT and sonography in 36 liver transplantation patients. AJR Am J Roentgenol. Aug 1991;157(2):303-6. [Medline].

  55. Stevens WR, Johnson CD, Stephens DH, et al. Fibrolamellar hepatocellular carcinoma: stage at presentation and results of aggressive surgical management. AJR Am J Roentgenol. May 1995;164(5):1153-8. [Medline].

  56. Stevens WR, Johnson CD, Stephens DH, et al. CT findings in hepatocellular carcinoma: correlation of tumor characteristics with causative factors, tumor size, and histologic tumor grade. Radiology. May 1994;191(2):531-7. [Medline].

  57. Trojan J, Schroeder O, Raedle J, et al. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol. Nov 1999;94(11):3314-9. [Medline].

  58. von Falck C, Rodt T, Shin HO, et al. F-18 FDG PET imaging of fibrolamellar hepatocellular carcinoma. Clin Nucl Med. Sep 2008;33(9):633-4. [Medline].

  59. Liu S, Wah Chan K, Tong J, Wang Y, Wang B, Qiao L. PET-CT scan is a valuable modality in the diagnosis of fibrolamellar hepatocellular carcinoma: a case report and a summary of recent literature. QJM. Jun 2011;104(6):477-83. [Medline].

  60. Crowe A, Knight CS, Jhala D, Bynon SJ, Jhala NC. Diagnosis of metastatic fibrolamellar hepatocellular carcinoma by endoscopic ultrasound-guided fine needle aspiration. Cytojournal. Jan 31 2011;8:2. [Medline]. [Full Text].

  61. Suen KC, Magee JF, Halparin LS, et al. Fine needle aspiration cytology of fibrolamellar hepatocellular carcinoma. Acta Cytol. Sep-Oct 1985;29(5):867-72. [Medline].

  62. Davenport RD. Cytologic diagnosis of fibrolamellar carcinoma of the liver by fine-needle aspiration. Diagn Cytopathol. 1990;6(4):275-9. [Medline].

  63. Perez-Guillermo M, Masgrau NA, García-Solano J, et al. Cytologic aspect of fibrolamellar hepatocellular carcinoma in fine-needle aspirates. Diagn Cytopathol. Sep 1999;21(3):180-7. [Medline].

  64. Kojiro M. Histopathology of liver cancers. Best Pract Res Clin Gastroenterol. Feb 2005;19(1):39-62. [Medline].

  65. Mansouri D, Van Nhieu JT, Couanet D, et al. Fibrolamellar hepatocellular carcinoma: a case report with cytological features in a sixteen-year-old girl. Diagn Cytopathol. Aug 2006;34(8):568-71. [Medline].

  66. Pinna AD, Iwatsuki S, Lee RG, et al. Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation. Hepatology. Oct 1997;26(4):877-83. [Medline].

  67. Ichikawa T, Federle MP, Grazioli L, et al. Fibrolamellar hepatocellular carcinoma: imaging and pathologic findings in 31 recent cases. Radiology. Nov 1999;213(2):352-61. [Medline].

  68. Pan Y, Wang ZM, Mou LJ, et al. Focal nodular hyperplasia of the liver: pathological analysis of 11 cases. Hepatobiliary Pancreat Dis Int. May 2004;3(2):199-203. [Medline].

  69. Berman MA, Burnham JA, Sheahan DG. Fibrolamellar carcinoma of the liver: an immunohistochemical study of nineteen cases and a review of the literature. Hum Pathol. Jul 1988;19(7):784-94. [Medline].

  70. Vasdev N, Nayak NC. CD99 expression in hepatocellular carcinoma: an immunohistochemical study in the fibrolamellar and common variant of the tumour. Indian J Pathol Microbiol. Oct 2003;46(4):625-9. [Medline].

  71. Sitzmann JV. Conversion of unresectable to resectable liver cancer: an approach and follow-up study. World J Surg. Nov-Dec 1995;19(6):790-4. [Medline].

  72. Soyer P, Roche A, Rougier P, et al. [Nonresectable fibrolamellar hepatocellular carcinoma: outcome of 4 cases treated by intra-arterial chemotherapy]. J Belge Radiol. Dec 1992;75(6):463-8. [Medline].

  73. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. Jul 24 2008;359(4):378-90. [Medline].

  74. Patt YZ, Hassan MM, Lozano RD, et al. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol. Feb 1 2003;21(3):421-7. [Medline].

  75. Pichlmayr R, Weimann A, Tusch G, et al. Indications and Role of Liver Transplantation for Malignant Tumors. Oncologist. 1997;2(3):164-170. [Medline].

  76. Schlitt HJ, Neipp M, Weimann A, et al. Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation. J Clin Oncol. Jan 1999;17(1):324-31. [Medline].

  77. Bartlett D, Di Bisceglie A, Dawson L. Cancer of the Liver. In: De Vita VT, Lawrence TS, Rosenberg S. Cancer: Principles & Practice of Oncology. 1. 8th ed. Philadelphia, Pa: Lippincott, Williams and Wilkins; 2008:1129-56.

  78. Epstein BE, Pajak TF, Haulk TL, et al. Metastatic nonresectable fibrolamellar hepatoma: prognostic features and natural history. Am J Clin Oncol. Feb 1999;22(1):22-8. [Medline].

  79. Friedman AC, Lichtenstein JE, Goodman Z, et al. Fibrolamellar hepatocellular carcinoma. Radiology. Dec 1985;157(3):583-7. [Medline].

  80. Lamberts R, Nitsche R, de Vivie RE, et al. Budd-Chiari syndrome as the primary manifestation of a fibrolamellar hepatocellular carcinoma. Digestion. 1992;53(3-4):200-9. [Medline].

  81. McLarney JK, Rucker PT, Bender GN, et al. Fibrolamellar carcinoma of the liver: radiologic-pathologic correlation. Radiographics. Mar-Apr 1999;19(2):453-71. [Medline].

  82. Steinmüller T, Jonas S, Neuhaus P. Review article: liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther. Jun 2003;17 Suppl 2:138-44. [Medline].

 
Previous
Next
 
Fibrolamellar carcinoma: Note the large tumor size in the background of a noncirrhotic liver.
CT scan showing fibrolamellar carcinoma with a large stellate central scar.
T1-weighted MRI of a fibrolamellar carcinoma in the left lobe of the liver.
T2-weighted MRI of a fibrolamellar carcinoma in the left lobe of the liver, demonstrating a heterogeneous appearance with a central scar.
Hematoxylin and eosin photomicrograph of fibrolamellar carcinoma. Note the thick fibrous lamellae within the tumor stroma.
Masson trichrome stain photomicrograph of fibrolamellar carcinoma depicting the collagen-containing lamellae within the tumor stroma.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.